284 related articles for article (PubMed ID: 9052722)
21. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
Picard V; Angelini E; Maillard A; Race E; Clavel F; Chêne G; Ferchal F; Molina JM
J Infect Dis; 2001 Sep; 184(6):781-4. PubMed ID: 11517441
[TBL] [Abstract][Full Text] [Related]
22. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.
Conway B; Wainberg MA; Hall D; Harris M; Reiss P; Cooper D; Vella S; Curry R; Robinson P; Lange JM; Montaner JS
AIDS; 2001 Jul; 15(10):1269-74. PubMed ID: 11426071
[TBL] [Abstract][Full Text] [Related]
23. Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.
Principi N; Marchisio P; Esposito S; Rossi P; Gattinara GC; Galli L; Gabiano C; Zuccotti GV; Orlandi P
AIDS Res Hum Retroviruses; 1998 Dec; 14(18):1653-9. PubMed ID: 9870319
[TBL] [Abstract][Full Text] [Related]
24. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities.
Gerondelis P; Archer RH; Palaniappan C; Reichman RC; Fay PJ; Bambara RA; Demeter LM
J Virol; 1999 Jul; 73(7):5803-13. PubMed ID: 10364332
[TBL] [Abstract][Full Text] [Related]
25. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group.
Pellegrin I; Izopet J; Reynes J; Denayrolles M; Montes B; Pellegrin JL; Massip P; Puel J; Fleury H; Segondy M
AIDS; 1999 Sep; 13(13):1705-9. PubMed ID: 10509572
[TBL] [Abstract][Full Text] [Related]
26. Delavirdine (Rescriptor) approved.
James JS
AIDS Treat News; 1997 Apr; (No 269):1-3. PubMed ID: 11364252
[TBL] [Abstract][Full Text] [Related]
27. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
[TBL] [Abstract][Full Text] [Related]
28. Clinically relevant genotype interpretation of resistance to didanosine.
Marcelin AG; Flandre P; Pavie J; Schmidely N; Wirden M; Lada O; Chiche D; Molina JM; Calvez V;
Antimicrob Agents Chemother; 2005 May; 49(5):1739-44. PubMed ID: 15855490
[TBL] [Abstract][Full Text] [Related]
29. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.
Coakley EP; Gillis JM; Hammer SM
AIDS; 2000 Jan; 14(2):F9-15. PubMed ID: 10708277
[TBL] [Abstract][Full Text] [Related]
30. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
Kuritzkes DR; Bassett RL; Johnson VA; Marschner IC; Eron JJ; Sommadossi JP; Acosta EP; Murphy RL; Fife K; Wood K; Bell D; Martinez A; Pettinelli CB
AIDS; 2000 Jul; 14(11):1553-61. PubMed ID: 10983642
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
[TBL] [Abstract][Full Text] [Related]
32. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
[TBL] [Abstract][Full Text] [Related]
33. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
Miranda LR; Götte M; Liang F; Kuritzkes DR
Antimicrob Agents Chemother; 2005 Jul; 49(7):2648-56. PubMed ID: 15980332
[TBL] [Abstract][Full Text] [Related]
34. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.
Iversen AK; Shafer RW; Wehrly K; Winters MA; Mullins JI; Chesebro B; Merigan TC
J Virol; 1996 Feb; 70(2):1086-90. PubMed ID: 8551567
[TBL] [Abstract][Full Text] [Related]
35. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.
Adjé C; Cheingsong R; Roels TH; Maurice C; Djomand G; Verbiest W; Hertogs K; Larder B; Monga B; Peeters M; Eholie S; Bissagene E; Coulibaly M; Respess R; Wiktor SZ; Chorba T; Nkengasong JN;
J Acquir Immune Defic Syndr; 2001 Apr; 26(5):501-6. PubMed ID: 11391173
[TBL] [Abstract][Full Text] [Related]
36. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virologic failure.
Balotta C; Violin M; Monno L; Bagnarelli P; Riva C; Facchi G; Berlusconi A; Lippi M; Rusconi S; Clementi M; Galli M; Angarano G; Moroni M
J Acquir Immune Defic Syndr; 2000 Jul; 24(3):232-40. PubMed ID: 10969347
[TBL] [Abstract][Full Text] [Related]
38. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.
Loemba H; Brenner B; Parniak MA; Ma'ayan S; Spira B; Moisi D; Oliveira M; Detorio M; Wainberg MA
Antimicrob Agents Chemother; 2002 Jul; 46(7):2087-94. PubMed ID: 12069959
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.
Shafer RW; Kozal MJ; Winters MA; Iversen AK; Katzenstein DA; Ragni MV; Meyer WA; Gupta P; Rasheed S; Coombs R
J Infect Dis; 1994 Apr; 169(4):722-9. PubMed ID: 8133086
[TBL] [Abstract][Full Text] [Related]
40. Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.
Flandre P; Descamps D; Joly V; Meiffrédy V; Tamalet C; Izopet J; Aboulker JP; Brun-Vézinet F
Antivir Ther; 2003 Feb; 8(1):65-72. PubMed ID: 12713066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
